Abstract
Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Current Bioactive Compounds
Title: Targeting Amoebiasis: Status and Developments
Volume: 3 Issue: 2
Author(s): A. Azam and S. M. Agarwal
Affiliation:
Keywords: Entamoeba histolytica, paromomycin, antiamoebic activity, antiplasmodial, Carbamic acid, Alkylphosphocholines
Abstract: Amoebiasis, a disease caused by Entamoeba histolytica, remains a major health problem that afflicts several million people worldwide. Moreover, in recent years there has been a rise in the number of reports with amebic brain abscess as well as in developed countries the microorganisms that cause diarrheal diseases are a cause of concern because of their potential to be used as bioterrorist agent. Metronidazole, an antiamoebic agent, is the drug of choice for treating amoebiasis in humans, but it has been shown to be both mutagenic and carcinogenic in bacteria and rodents respectively. The completely safe treatment for this disease does not exist at present and therefore newer and safer agents are required either from synthetic or natural resources. This review covers brief description of the disease, plant secondary metabolites and synthetic compounds that have exhibited moderate to high activity in vitro and in vivo bioassays against E. histolytica. The review also discusses some of the key biochemical targets that are unique and vital for the existence and growth of the parasite which are being further exploited so as to search for therapeutically active antiamoebic agents.
Export Options
About this article
Cite this article as:
Azam A. and Agarwal M. S., Targeting Amoebiasis: Status and Developments, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809590
DOI https://dx.doi.org/10.2174/157340707780809590 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Current Pharmaceutical Design Community-Acquired Pneumonia in Children
Recent Patents on Inflammation & Allergy Drug Discovery Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Percutaneous Treatment of Hydatid Liver Cyst
Recent Patents on Anti-Infective Drug Discovery Pharmacokinetic Mechanisms for Reduced Toxicity of Irinotecan by Coadministered Thalidomide
Current Drug Metabolism Recent Developments of Magnetic Nanoparticles for Theranostics of Brain Tumor
Current Drug Metabolism Bedside Lung Ultrasound in the Care of the Critically Ill
Current Respiratory Medicine Reviews Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Opportunistic Pathogens in Diabetic Foot Lesions
Current Diabetes Reviews Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand
Current Radiopharmaceuticals HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells
Current Topics in Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Production of 68Ga-citrate Based on a SnO2 Generator for Short-Term Turpentine Oil-Induced Inflammation Imaging in Rats
Current Radiopharmaceuticals